ACTengine patient recruitment remains on track; as of end of July, a total of 27 patients have been treated with IMA201, IMA202 or IMA203 across different cancer indicationsTCR Bispecifics pipeline
https://immatics.com/: Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME
Immatics
Preclinical data highlights: candidate targets an HLA-A 02-bound peptide derived from preferentially expressed antigen in melanoma (PRAME).
The target peptide was selected and validated based on quantitative mass spectrometry data from Immatics proprietary XPRESIDENT platform and is prevalent in many solid tumor indications including lung, ovarian and breast cancer as well as other solid cancer types.
Over 50 different human wild-type TCRs recognizing the PRAME target peptide were systematically evaluated using Immatics XCEPTOR platform. Two TCRs with high avidity and specificity were selected and affinity-enhanced by at least 1,000-fold while retaining specificity through the XPRESIDENT